PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT

This adverse event was reported 874 times

PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 CABOTEGRAVIR AND RILPIVIRINE 459 0.0702
1 RILPIVIRINE 272 0.0381
2 CABOTEGRAVIR 254 0.0310
3 IBALIZUMAB 11 0.0204
4 CABOTEGRAVIR SODIUM 31 0.0193
5 FOSTEMSAVIR TROMETHAMINE 3 0.0123
6 DOLUTEGRAVIR SODIUM AND LAMIVUDINE 32 0.0089
7 DORAVIRINE 4 0.0051
8 TIRBANIBULIN 1 0.0040
9 DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE 10 0.0036
See all drugs enriched for association with PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT